Supplier details - Dermicus Telehealth Platform

About Gnosco AB

Dermicus was developed by Gnosco, in partnership with Karolinska University Teaching Hospital in Stockholm in 2012. Dermicus was CE marked in 2014 and, from July 2019, has been live in the NHS. An independent evaluation report of NHS customer benefits states: • Waiting times between referral and review have decreased dramatically. The average wait from referral to first consultant review was 26 days and now referrals using the Dermicus platform have a wait time of 0.6 days. • Most patients were happy and satisfied with the new approach to skin cancer diagnosis, finding it fast, easy, reassuring and an improvement to skin examination. • Dermicus is not overly complex - referring clinicians have felt able to adopt the new way of working easily. • Outpatient cost saving - by moving from face-to-face to teleconsultations. The Dermicus platform is of value for the COVID-19 pandemic as it crucially keeps older patients out of secondary care and supports efficient management of backlog.

http://www.dermicus.co.uk/

Contact details

Contact name

Daniel Eliasson

Department

Business Development

Contact details

020 8144 9739

Daniel.eliasson@gnosco.se

Contact name

Johan Hjalmarsson

Department

Product Management

Contact details

020 8144 9739

johan.hjalmarsson@gnosco.se

Solution information last reviewed: Wednesday, 13 April 2022